Has GBL replaced GHB in recreational settings?
By:
References
- Marinelli E, Beck R, Malvasi A, Lo Faro A, Zaami S. Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management. Arh Hig Rada Toksikol 2020;71:19–26. doi: 10.2478/aiht-2020-71-3314
- Busardò FP, Gottardi M, Tini A, Minutillo A, Sirignano A, Marinelli E, Zaami S. Replacing GHB with GBL in recreational settings: a new trend in chemsex. Curr Drug Metab 2018;19:1080–5. doi: 10.2174/13892002196661809 25090834
- Busardò FP, Vaiano F, Mannocchi G, Bertol E, Zaami S, Marinelli E. Twelve months monitoring of hair GHB decay following a single dose administration in a case of facilitated sexual assault. Drug Test Anal 2017;9:953–6. doi: 10.1002/dta.2100
- World Health Organization (WHO). γ-Butyrolactone (GBL). Who Expert Committee on Drug Dependence: thirty-fifth report. WHO Technical Report Series 973. Geneva: WHO; 2012. p. 14–5.
- Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome. Eur Rev Med Pharmacol Sci 2015;19:4654–63. PMID: 26698265
- McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75:3–9. doi: 10.1016/j.drugalcdep.2004.01.012
- Busardò FP, Bertol E, Vaiano F, Baglio G, Montana A, Barbera N, Zaami S, Romano G. Post mortem concentrations of endogenous gamma hydroxybutyric acid (GHB) and in vitro formation in stored blood and urine samples. Forensic Sci Int 2014;243:144–8. doi: 10.1016/j.forsciint.2014.07.019
- van Amsterdam J, Brunt T, Pennings E, van den Brink W. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. Regul Toxicol Pharmacol 2014;70:507–13. doi: 10.1016/j.yrtph.2014.08.014
- Busardò FP, Pichini S, Zaami S, Pacifici R, Kintz P. Hair testing of GHB: an everlasting issue in forensic toxicology. Clin Chem Lab Med 2018;56:198–208. doi: 10.1515/cclm-2017-0397
- Kyriakou C, Pellegrini M, García-Algar O, Marinelli E, Zaami S. Recent trends in analytical methods to determine new psychoactive substances in hair. Curr Neuropharmacol 2017;15:663–81. doi: 10.2174/1570159X15666161111112545
- Busardò FP, Kyriakou C, Tittarelli R, Mannocchi G, Pantano F, Santurro A, Zaami S, Baglìo G. Assessment of the stability of mephedrone in ante-mortem and post-mortem blood specimens. Forensic Sci Int 2015;256:28–37. doi: 10.1016/j. forsciint.2015.07.021
- Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011;3:417–25. doi: 10.1002/dta.292
- Beck R, Matanović SM, Zibar L. Gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol addiction: a serious health threat. Arh Hig Rada Toksikol 2019;70:149–50. doi: 10.2478/aiht-2019-70-3295
Language: English, Croatian, Slovenian
Page range: 167 - 168
Published on: Jun 29, 2020
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2020 Anastasio Tini, Alessandro Del Rio, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution 4.0 License.